Olaparib Oral Capsule

DRUG2 trials

Sponsors

ARCAGY/ GINECO GROUP, AZ-VUB

Conditions

Advanced Cancers Harbouring Mutations in HRGEndometrial Carcinoma

Phase 2

UTOLA: UTerin OLAparib

CompletedNCT03745950

ARCAGY/ GINECO GROUPEndometrial Carcinoma

Start: 2019-02-01End: 2024-09-24Updated: 2024-12-04

Efficacy of Olaparib in Advanced Cancers Occurring in Patients With Germline Mutations or Somatic Tumor Mutations in Homologous Recombination Genes

Active, not recruitingNCT03967938

AZ-VUBAdvanced Cancers Harbouring Mutations in HRG

Start: 2019-02-07End: 2025-12-31Target: 540Updated: 2024-08-19

Related Papers

Data from ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial

2026-04-01

Circulating tumor DNA for prognostication and monitoring in patients with metastatic endometrial carcinoma treated with olaparib: validation in the GINECO-UTOLA trial.

2026-01-15

Association between molecular classification and overall survival in patients with metastatic endometrial carcinoma: ancillary results of the UTOLA phase II GINECO trial.

2025-11-21

Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial

Nature Communications2025-08-264 citations

The PENDOR study: establishment of a panel of patient-derived tumor organoids from endometrial cancer to assess efficacy of PARP inhibitors.

2025-02-111 citations

555 Association between molecular heterogeneity and prognosis in non-P53 metastatic endometrial carcinoma: ancillary analysis of the UTOLA phase II GINECO trial

2024-03-01

Multicentre randomized phase II trial of olaparib as maintenance therapy in platinum-sensitive advanced endometrial carcinoma: The GINECO-UTOLA study.

Journal of Clinical Oncology2020-05-204 citations